Accessibility Tools

Skip to main content

Real-world Outcomes Following Initiation of Abemaciclib in Patients With Brain Metastases Secondary to HR+/HER2- Metastatic Breast Cancer

Rapid Reactions, Women’s Health
SABCS 2023 HR+/HER2-
Videos
Dr Rugo of the University of California San Francisco Comprehensive Cancer Center reports on the outcomes of a retrospective study of patients with metastatic breast cancer and brain metastases treated with abemaciclib.

Related Items

Hormone-Free Copper IUD Gets FDA Nod
May 2025, Vol 2, No 5
FDA News, Women’s Health
Updated TRICARE Maternity Services in 2025: An Overview
May 2025, Vol 2, No 5
TRICARE News Roundup, Women’s Health
FDA OKs Fam-Trastuzumab Deruxtecan-nxki for Unresectable or Metastatic HR-Positive, HER2-Low or HER2-Ultralow Breast Cancer
March 2025, Vol 2, No 3
FDA News, Women’s Health
Study on Early Menopause and Women Who Served in the Gulf War Underscores Importance of Medical History
November 2024, Vol 1, No 1
Women’s Health
Primary Analysis of HER2CLIMB-02: Addition of Tucatinib to Trastuzumab Emtansine in Previously Treated Patients with HER2-Positive Metastatic Breast Cancer
Videos
Rapid Reactions
INAVO120 Phase III Study: Treatment of Patients With PIK3CA-mutant, HR+/HER2- Locally Advanced or Metastatic Breast Cancer With Invavolisib in Combination With Palbociclib and Fulvestrant
Videos
Rapid Reactions
Abemaciclib and NSAI for 1L Treatment of HR+/HER2- Advanced Breast Cancer: Long-term Survival Data Reported
Videos
Rapid Reactions, Women’s Health